Abstract
Differences in the efficacy of second-line therapies on the biochemical control of acromegaly in patients with GH secreting pituitary neuroendocrine tumors (Pit-NETs) and GH and PRL cosecreting Pit-NETs
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have